Your browser doesn't support javascript.
loading
Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).
Jõgi, Piia; Soeorg, Hiie; Ingerainen, Diana; Soots, Mari; Lättekivi, Freddy; Naaber, Paul; Toompere, Karolin; Peterson, Pärt; Haljasmägi, Liis; Zusinaite, Eva; Vaas, Hannes; Pauskar, Merit; Shablinskaja, Arina; Kaarna, Katrin; Paluste, Heli; Kisand, Kai; Oona, Marje; Janno, Riina; Lutsar, Irja.
Affiliation
  • Jõgi P; Children's Clinic of Tartu University Hospital, N. Lunini 6, 50406 Tartu, Estonia; Department of Pediatrics, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, 50406 Tartu, Estonia. Electronic address: piia.jogi@kliinikum.ee.
  • Soeorg H; Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Ingerainen D; Family Doctor Center "Järveotsa", Õismäe tee 179, 13517 Tallinn, Estonia.
  • Soots M; Family Doctor Center "Kuressaare", Aia 25a, 93815 Kuressaare, Estonia.
  • Lättekivi F; Department of Pathophysiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia; Development Centre, United Chancery Service, Tartu University Hospital, Puusepa 8, 50406 Tartu, Estonia.
  • Naaber P; Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia; SYNLAB Estonia, Tallinn, Estonia.
  • Toompere K; Department of Epidemiology and Biostatistics, Institute of Family Medicine and Public Health, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Peterson P; Molecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Haljasmägi L; Molecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Zusinaite E; Institute of Technology, Faculty of Science and Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
  • Vaas H; Children's Clinic of Tartu University Hospital, N. Lunini 6, 50406 Tartu, Estonia.
  • Pauskar M; Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Shablinskaja A; Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Kaarna K; Development Centre, United Chancery Service, Tartu University Hospital, Puusepa 8, 50406 Tartu, Estonia; Clinical Research Centre, Institute of Clinical Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Paluste H; Ministry of Social Affairs, Republic of Estonia, Suur-Ameerika 1, 10122 Tallinn, Estonia.
  • Kisand K; Molecular Pathology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Oona M; Department of Family Medicine, Institute of Family Medicine and Public Health, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
  • Janno R; Development Centre, United Chancery Service, Tartu University Hospital, Puusepa 8, 50406 Tartu, Estonia.
  • Lutsar I; Department of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia.
Vaccine ; 39(38): 5376-5384, 2021 09 07.
Article in En | MEDLINE | ID: mdl-34393019

Full text: 1 Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Vaccine Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Vaccine Year: 2021 Type: Article